Astellas Pharma (OTCMKTS:ALPMY) Raised to Strong-Buy at Zacks Research

Astellas Pharma (OTCMKTS:ALPMY) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Astellas Pharma has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Up 1.4%

OTCMKTS ALPMY opened at $13.35 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09. The company has a market capitalization of $24.16 billion, a P/E ratio of 12.43 and a beta of 0.07. Astellas Pharma has a one year low of $9.22 and a one year high of $17.35. The stock has a 50 day moving average price of $14.31 and a 200-day moving average price of $14.65.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. The firm had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.28 billion. As a group, equities analysts predict that Astellas Pharma will post 1.34 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).